Lenvatinib in Second Line Endometrial Carcinoma

Phase 2

Withdrawn

• Conditions: Endometrial Neoplasms
• Interventions: Drug: Doxorubicin; Drug: Lenvatinib

• Registration Number: NCT03005015
• Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Brief Summary

The primary objective of this multicenter, randomized phase II trial is to assess the efficacy, as measured by progression-free survival (PFS), of lenvatinib compared to doxorubicin in advanced or recurrent endometrial cancer.

The main secondary objective is to evaluate the predictive value of Ang-2 on lenvatinib activity and establishing a cutoff value as potential selection criteria for phase III.

Other secondary objectives are to assess the tolerability and safety of lenvatinib in this setting and overall survival, response and disease control.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-08-18
• Status Verified: 2016-12
• Study First Submitted QC: 2016-12-23
• Last Update Submitted: 2016-12-23
• Study First Posted: 2016-12-29
• Last Update Posted: 2016-12-29
• Study Start: 2017-01
• Primary Completion: 2020-07

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

• Female subjects age ≥18 years at the time of informed consent
• World Health Organization (WHO) Performance Status of 0 or 1
• Patients with histologically confirmed endometrial cancer including serous-papillary and clear cell histologies. Uterine carcinosarcomas are allowed.
• Radiographic evidence of disease progression according to RECIST 1.1 after 1 prior systemic, platinum-based chemotherapy regimen for metastatic or primary unresectable endometrial carcinoma for which no surgical or radiotherapy treatment options exist.
• Patients with disease progression following platinum-based chemotherapy administered as either adjuvant or neoadjuvant treatment are also eligible.
• Patients may have received prior radiotherapy and / or adjuvant chemotherapy for early high-risk disease
• Patients may not have received prior treatment with anthracyclines
• Blood samples available for retrospective central assessment of Ang-2 level
• Patients may have had prior therapy providing the following conditions are met:
• Surgery and radiation therapy: wash-out period of 14 days and subjects must have recovered adequately from any toxicity and/or complications from radiotherapy and major surgery prior to starting therapy.
• Systemic anti-tumor therapy or any investigational agent: wash-out period of 21 days (or 5 x half-life)
• Recovery from any toxic effects of prior therapy to ≤ Grade 1 per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v4.) except alopecia
• Adequate contraceptive measures
• Signed written informed consent

Exclusion Criteria

• Inadequate hematologic, renal and hepatic functions
• Abnormal cardiac function

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Doxorubicin	Doxorubicin	Doxorubicin 60 mg/m² iv bolus every 3 weeks. Treatment is continued for a maximum of 6 cycles or until unacceptable toxicity, progressive disease or patient withdrawal.
Lenvatinib	Lenvatinib	Lenvatinib 24 mg orally every day. Treatment is continued until unacceptable toxicity, progressive disease or patient withdrawal

Primary Outcome Measures

Name	Time	Method
Progression free survival (PFS)	2.5 years	PFS assessed by Response Evaluation Criteria in Solid Tumors (RECIST

Trial Locations

Locations (1)

Centre Hospitalier Universitaire Vaudois; 🇨🇭 Lausanne, Switzerland